Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer Sequist LVOncologist 2007[Mar]; 12 (3): 325-30Inhibiting epidermal growth factor receptor (EGFR) signaling has proven to be an effective strategy for treating non-small cell lung cancer (NSCLC) patients and the first generation of agents developed for this purpose, gefitinib and erlotinib, stimulated a unique escalation in both biologic and clinical research within the field. Second-generation EGFR-targeted agents that aim to further improve patient outcomes are now in preclinical and clinical trials. This review discusses four promising agents that are currently being studied in NSCLC: EKB-569, HKI-272, CI-1033, and ZD6474.|Aminoquinolines[MESH]|Aniline Compounds[MESH]|Antineoplastic Agents/*therapeutic use[MESH]|Carcinoma, Non-Small-Cell Lung/*drug therapy[MESH]|ErbB Receptors/*antagonists & inhibitors[MESH]|Humans[MESH]|Lung Neoplasms/*drug therapy[MESH]|Morpholines/therapeutic use[MESH]|Organic Chemicals/therapeutic use[MESH]|Piperidines/therapeutic use[MESH]|Protein Kinase Inhibitors/*therapeutic use[MESH]|Quinazolines/therapeutic use[MESH]|Quinolines/therapeutic use[MESH] |
